ASSOCIATION BETWEEN IMMUNOHISTOCHEMICAL EXPRESSION OF PROGRAMMED DEATH - LIGAND 1 (PD-L1) AND CLINICOPATHOLOGICAL PARAMETERS IN INVASIVE BREAST CARCINOMA

Adeodata Lily Wibisono; Delyuzar; Joko S. Lukito

Volume : VIII, Issue : V, May - 2019

ASSOCIATION BETWEEN IMMUNOHISTOCHEMICAL EXPRESSION OF PROGRAMMED DEATH - LIGAND 1 (PD-L1) AND CLINICOPATHOLOGICAL PARAMETERS IN INVASIVE BREAST CARCINOMA

Adeodata Lily Wibisono, Delyuzar, Joko S. Lukito

Abstract :

Programmed Death-Ligand 1 (PD-L1) overexpression as a predictive biomarker for anti-PD-1/PD-L1 therapy effectiveness has been observed in various human malignancies and contributes to poor prognosis. However, this is still controversial in east malignancy. This cross-sectional analytic study of 37 invasive east carcinoma patients� formalin-fixed paraffin-embedded blocks was conducted to assess the association between immunohistochemical expression of PD-L1 and various clinicopathological parameters. PD-L1 was expressed in 48.6% of the invasive east carcinoma specimens. PD-L1 positive expression was significantly associated with larger tumor size, higher histological grade, high stromal TILs, and aggressive molecular subtype, such as triple negative east cancer. The association of PD-L1 expression with adverse clinicopathological characteristics indicates that PD-L1 expression can be considered as a prognostic biomarker for invasive east carcinoma, and may be helpful in selecting potential patients for anti-PD-1/PD-L1 therapy.